Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

47.98 +0.20 (+0.42%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Novo Nordisk Arms Wegovy to Be a Triple Threat
Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders 
Via MarketBeat
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough... 
Via Benzinga
Exposures Product Safety
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the... 
Via Benzinga
How Is The Market Feeling About Sanofi?
Via Benzinga
(SNY) - Analyzing Sanofi's Short Interest
Via Benzinga
Why the dividend investor may take a look at NASDAQ:SNY.
Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics. 
Via Chartmill
Why Is Auddia (AUUD) Stock Up 192% Today?
Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
AIRC Stock Alert: Blackstone Is Taking Apartment Income REIT Private
Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private. 
Via InvestorPlace
Sanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts
Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster
Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
What's Going On European Pharma Giant AstraZeneca Stock On Wednesday?
Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca... 
Via Benzinga
NASDAQ:SNY is an undervalued gem with solid fundamentals.
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath'
Krispy Kreme's partnership with McDonald's has led to a surge in stock prices. Investors are turning to insulin stocks to capitalize on the growing demand. 
Via Benzinga
To the Moon and Beyond: 7 Stocks With Cosmic Potential
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential. 
Via InvestorPlace
Passport to Profits: 7 Global Growth Gems to Diversify Your Holdings
With certain sectors in the domestic market appearing overstretched, these global growth stocks may offer better opportunities. 
Via InvestorPlace
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. 
Via InvestorPlace
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
Via Benzinga
3 Cash Cow Dividend Stocks for Outsized Income & Upside
With uncertainty again weighing on the market, investors can take shelter under these cash cow dividend stocks. 
Via InvestorPlace
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why 
Via MarketBeat
Topics Lawsuit
Exposures Financial Legal
Move Over Magnificent 7, Say Hello to the GRANOLAS
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods. 
Via InvestorPlace
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests
The FDA put studies in eczema and asthma treatment on clinical hold. 
Via Investor's Business Daily
Exposures Product Safety
Cruising For A Bruising
We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft... 
Via Talk Markets
Topics Economy
Exposures Economy Interest Rates
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Don't count these companies out too soon. 
Via The Motley Fool
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. 
Via InvestorPlace
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
What's Going On Eli Lilly Stock Thursday?
Eli Lilly's impressive stock surge, better-than-expected Q4 results, and positive analyst reviews. 
Via Benzinga
Novo Nordisk To Up Production Capacity As Parent Buys Catalent
NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash. 
Via Investor's Business Daily
CytoReason's AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development
Click here to learn more about CytoReason and how to invest through OurCrowd.  
Via Benzinga
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.